[O-31] Oral Session 31
Clinical trial and Regenerative medicine 1 E

[O-31-5] Benefit of eculizumab for a broad range of patients with NMOSD: findings from the PREVENT study

^○Ichiro Nakashima¹, Kazuo Fujihara^2,3, Achim Berthele⁴, Ho Jin Kim⁵, Michael Levy^6,7, Celia Oreja-gueva⁸, Jacqueline Palace⁹, Sean J. Pittock¹⁰, Murat Terzi¹¹, Natalia Totolyan¹², Shanthi Viswanathan¹³, Kai-chen Wang^14,15, Amy Pace¹⁶, Marcus Yountz¹⁶, Larisa Miller¹⁶, Imran Tanvir¹⁶, Róisín Armstrong¹⁶, Dean M. Wingerchuk¹⁰ (1.Tohoku Medical and Pharmaceutical University, Japan, 2.Tohoku University, 3.Fukushima Medical University, 4.Technical University of Munich, 5.Research Institute and Hospital, Goyang, 6.Johns Hopkins University, 7.Massachusetts General Hospital, 8.Hospital Universitario Clínico San Carlos, 9.John Radcliffe Hospital, 10.Mayo Clinic, 11.Ondokuz Mayis University, 12.First Pavlov State Medical University of St Petersburg, 13.Kuala Lumpur Hospital, 14.Cheng-Hsin General Hospital, 15.National Yang Ming University, 16.Alexion Pharmaceuticals)